FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Res Commun / Evaluation of gastrointestinal tract lesions and serum malon...
Veterinary research communications2024; 48(4); 2343-2355; doi: 10.1007/s11259-024-10415-y

Evaluation of gastrointestinal tract lesions and serum malondialdehyde levels after repeated oral administration of phenylbutazone in horses.

Abstract: Phenylbutazone (PBZ) is a widely used nonsteroidal anti-inflammatory drug for horses. However, because of its gastrointestinal side effects, its administration requires careful attention in veterinary practice. Malondialdehyde (MDA) is a serum biomarker associated with increased damage to the equine gastrointestinal system. This study investigated the hematological effects and alterations in the gastrointestinal tract and assessed serum MDA concentrations following repeated oral PBZ administration at clinical doses. Fourteen horses were randomly divided into control and treatment groups. All horses in the treatment group were administered 4.4 milligrams per kilogram of body weight of PBZ syrup orally twice a day for 7 days, whereas the control group received syrup as a placebo. The development of gastrointestinal side effects was investigated using gastroscopy, abdominal ultrasound, and fecal pH; serum MDA concentrations were assessed using a commercially available enzyme-linked immunosorbent assay kit. Data were compared between PBZ-treated and control horses before and after the treatment period. The treatment group exhibited decreased albumin and total protein concentrations. Moreover, this group exhibited a higher thickness of the right dorsal colon wall (p = 0.03) and had higher scores for squamous gastric ulcers (p = 0.01). Fecal pH was lower in the treatment group than in the control group after PBZ administration (p < 0.01). Although MDA concentrations were higher in the treatment group after PBZ administration, they did not differ significantly from those of the control group. This study highlighted the changes in hematological and gastrointestinal lesions resulting from PBZ administration in horses at clinical doses, even without clinical signs. However, MDA may not be an optimal biomarker for the early detection of gastrointestinal damage due to PBZ treatment in horses.
© 2024. The Author(s).
Get Full Text
Publication Date: 2024-05-21 PubMed ID: 38771448PubMed Central: PMC11315746DOI: 10.1007/s11259-024-10415-yGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study gauged the impact of phenylbutazone, an anti-inflammatory medication, on the digestive system in horses. Results indicate significant physiological changes as a result of the drug, including decreasing protein levels and increasing the risk of gastric ulcers, but suggested that malondialdehyde may not be effective for early detection of gastrointestinal damage.

Objective and Methodology

  • The objective of the study was to evaluate the effects of phenylbutazone, a common anti-inflammatory medication used in horses, on the horse’s gastrointestinal system. The research also sought to establish the efficacy of malondialdehyde as a serum biomarker in detecting damage caused by the use of phenylbutazone.
  • The study involved fourteen horses which were divided randomly into two groups – a control group and a treatment group. The treatment group received phenylbutazone for seven days, whereas the control group was administered a placebo.
  • The team used gastroscopy, abdominal ultrasound, and fecal pH tests to investigate potential gastrointestinal side effects. The researchers also used an enzyme-linked immunosorbent assay kit to measure serum malondialdehyde concentrations.
  • The scientists compared the data from the treatment group and the control group, both prior to and after the treatment phase.

Results and Findings

  • The research revealed that the administration of phenylbutazone resulted in an observable decrease in total protein and albumin levels in horses.
  • There were marked changes in the gastrointestinal system after the administration of PBZ. The digestive tract showed a higher thickness of the right dorsal colon wall, while there were higher scores for squamous gastric ulcers.
  • Notably, the treatment group also displayed lower fecal pH levels when compared to the control group after Phenylbutazone administration.
  • While, malondialdehyde (MDA) concentrations were elevated in the treatment group following Phenylbutazone administration, they did not significantly deviate from those in the control group. This outcome indicates that malondialdehyde might not be an ideal biomarker when it comes to identification of early gastrointestinal damage due to Phenylbutazone treatment in horses.

Conclusion

  • The study effectively demonstrated that Phenylbutazone administration resulted in notable physiological changes and observable damage to the gastrointestinal system of the horses, even without obvious clinical symptoms.
  • However, the study suggested that malondialdehyde concentrations may not be a reliable method for the early detection of such damage.

Cite This Article

APA
Tesena P, Vinijkumthorn R, Preuksathaporn T, Piyakul P, Chotikaprakal T, Sirireugwipas R, Wong-Aree K, Prapaiwan N. (2024). Evaluation of gastrointestinal tract lesions and serum malondialdehyde levels after repeated oral administration of phenylbutazone in horses. Vet Res Commun, 48(4), 2343-2355. https://doi.org/10.1007/s11259-024-10415-y

Publication

Veterinary research communications
ISSN: 1573-7446
NlmUniqueID: 8100520
Country: Switzerland
Language: English
Volume: 48
Issue: 4
Pages: 2343-2355

Researcher Affiliations

Tesena, Parichart
  • Department of Clinical Sciences and Public Health, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, 73170, Thailand.
Vinijkumthorn, Ruethaiwan
  • Department of Clinical Sciences and Public Health, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, 73170, Thailand.
Preuksathaporn, Titirat
  • Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, 73170, Thailand.
Piyakul, Poonnada
  • Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, 73170, Thailand.
Chotikaprakal, Thanapon
  • Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, 73170, Thailand.
Sirireugwipas, Rannaree
  • Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, 73170, Thailand.
Wong-Aree, Kanokpich
  • Veterinary and Remount Department, Royal Thai Army Animal Hospital, Nakhon Pathom, 73000, Thailand.
Prapaiwan, Nawarus
  • Department of Clinical Sciences and Public Health, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, 73170, Thailand. nawarus.pra@mahidol.edu.

MeSH Terms

  • Animals
  • Horses
  • Phenylbutazone / administration & dosage
  • Phenylbutazone / adverse effects
  • Malondialdehyde / blood
  • Horse Diseases / chemically induced
  • Horse Diseases / drug therapy
  • Horse Diseases / blood
  • Administration, Oral
  • Male
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Female
  • Gastrointestinal Diseases / veterinary
  • Gastrointestinal Diseases / chemically induced
  • Gastrointestinal Diseases / blood
  • Gastrointestinal Tract / drug effects

Conflict of Interest Statement

The authors declare no competing interests.

References

This article includes 59 references
  1. Andrew F, Bernard W, Byars D, Cohen N, Divers T, MacAllister C, Merritt A, Murray M, Orsini J, Snyder J. Recommendations for the diagnosis and treatment of equine gastric ulcer syndrome (EGUS). Equine Vet Educ 1999;11:262–272.
    doi: 10.1111/j.2042-3292.1999.tb00961.xgoogle scholar: lookup
  2. Andrews FM, Reinemeyer CR, McCracken MD, Blackford JT, Nadeau JA, Saabye L, Sotell M, Saxton A. Comparison of endoscopic, necropsy and histology scoring of equine gastric ulcers. Equine Vet J 2002;34(5):475–478.
    doi: 10.2746/042516402776117827pubmed: 12358050google scholar: lookup
  3. Andrews FM, Frank N, Sommardahl CS, Buchanan BR, Elliott SB, Allen VA. Effects of intravenously administrated omeprazole on gastric juice pH and gastric ulcer scores in adult horses. J Vet Intern Med 2006;20(5):1202–1206.
    doi: 10.1892/0891-6640(2006)20[1202:eoiaoo]2.0.co;2pubmed: 17063717google scholar: lookup
  4. Argenzio RA. Comparative pathophysiology of nonglandular ulcer disease: a review of experimental studies. Equine Vet J Suppl 1999;(29):19–23.
    pubmed: 10696288doi: 10.1111/j.2042-3306.1999.tb05163.xgoogle scholar: lookup
  5. Banse HE, Andrews FM. Equine glandular gastric disease: prevalence, impact and management strategies. Vet Med (Auckl) 2019;10:69–76.
    doi: 10.2147/VMRR.S174427pmc: PMC6642651pubmed: 31406687google scholar: lookup
  6. Barletta M, Quandt J, Reed R. Equine anesthesia and pain management. .
  7. Bauck AG, Vidyasagar S, Freeman DE. Mechanisms of bicarbonate secretion in the equine colon ex vivo. Am J Vet Res 2022;83(8):1–10.
    doi: 10.2460/ajvr.22.03.0045pubmed: 35895780google scholar: lookup
  8. Blobaum AL, Marnett LJ. Structural and functional basis of cyclooxygenase inhibition. J Med Chem 2007;50(7):1425–1441.
    doi: 10.1021/jm0613166pubmed: 17341061google scholar: lookup
  9. Burke CR, Meier S, McDougall S, Compton C, Mitchell M, Roche JR. Relationships between Endometritis and metabolic state during the transition period in pasture-grazed dairy cows. J Dairy Sci 2010;93(11):5363–5373.
    doi: 10.3168/jds.2010-3356pubmed: 20965352google scholar: lookup
  10. Chiaradia E, Avellini L, Rueca F, Spaterna A, Porciello F, Antonioni MT, Gaiti A. Physical exercise, oxidative stress and muscle damage in racehorses. Comp Biochem Physiol B Biochem Mol Biol 1998;119(4):833–836.
    doi: 10.1016/s0305-0491(98)10001-9pubmed: 9787774google scholar: lookup
  11. Clark-Price S, Mama K. Equine Anesthesia and co-existing Disease. .
  12. Cohen ND, Carter GK, Mealey RH, Taylor TS. Medical management of right dorsal colitis in 5 horses: a retrospective study (1987–1993). J Vet Intern Med 1995;9(4):272–276.
    doi: 10.1111/j.1939-1676.1995.tb01079.xpubmed: 8523325google scholar: lookup
  13. Cook VL, Blikslager AT. The use of nonsteroidal anti-inflammatory drugs in critically ill horses. J Vet Emerg Crit Care (San Antonio) 2015;25(1):76–88.
    doi: 10.1111/vec.12271pubmed: 25521286google scholar: lookup
  14. Davis JL. Nonsteroidal anti-inflammatory drug associated right dorsal colitis in the horse. Equine Vet Educ 2017;29(2):104–113.
    doi: 10.1111/eve.12454google scholar: lookup
  15. El-Ashker M, El-Khodery S, Metwally N, Hussein H, El-Boshy M. Prognostic significance of oxidative stress markers in colitis associated with phenylbutazone administration in draft horses. J Equine Vet Sci 2012;32(3):146–152.
    doi: 10.1016/j.jevs.2011.08.008google scholar: lookup
  16. El-Deeb W, Iacob O, Fayez M, Elgioushy M, Shawaf T, Ibrahim A. Acute phase proteins, interleukin-6, tumor necrosis factor, nitric oxide and oxidative stress markers in horses with cutaneous habronemosis under field condition. Vet Parasitol 2018;255:20–25.
    doi: 10.1016/j.vetpar.2018.03.023pubmed: 29773131google scholar: lookup
  17. Engevik AC, Kaji I, Goldenring JR. The physiology of the gastric parietal cell. Physiol Rev 2020;100(2):573–602.
    doi: 10.1152/physrev.00016.2019pmc: PMC7327232pubmed: 31670611google scholar: lookup
  18. Fitzpatrick FA. Cyclooxygenase enzymes: regulation and function. Curr Pharm Des 2004;10(6):577–588.
    doi: 10.2174/1381612043453144pubmed: 14965321google scholar: lookup
  19. Flood J, Stewart AJ. Non-steroidal anti-inflammatory drugs and associated toxicities in horses. Anim (Basel) 2022;12(21).
    pmc: PMC9655344pubmed: 36359062doi: 10.3390/ani12212939google scholar: lookup
  20. Galvin N, Dillon H, McGovern F. Right dorsal colitis in the horse: minireview and reports on three cases in Ireland. Ir Vet J 2004;57(8):467–473.
    doi: 10.1186/2046-0481-57-8-467pmc: PMC3113814pubmed: 21851661google scholar: lookup
  21. Garner HE, Moore JN, Johnson JH, Clark L, Amend JF, Tritschler LG, Coffmann JR, Sprouse RF, Hutcheson DP, Salem CA. Changes in the caecal flora associated with the onset of laminitis. Equine Vet J 1978;10(4):249–252.
    doi: 10.1111/j.2042-3306.1978.tb02273.xpubmed: 738266google scholar: lookup
  22. Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis in the horse - a review. Vet J 2006;171(1):51–69.
    doi: 10.1016/j.tvjl.2004.07.008pubmed: 16427582google scholar: lookup
  23. Hajimohammadi A, Ghane M, Ghari Tehrani M, Paravar B, Mirzaei A, Razavi S, Nikzad M. Association of the severity of colic in horses with oxidative stress biomarkers, acute-phase proteins, and certain trace elements. J Equine Sci 2023;34(3):73–81.
    doi: 10.1294/jes.34.73pmc: PMC10534060pubmed: 37781567google scholar: lookup
  24. Hewetson M, Tallon R. Equine squamous gastric disease: prevalence, impact and management. Vet Med (Auckl) 2021;12:381–399.
    doi: 10.2147/VMRR.S235258pmc: PMC8725839pubmed: 35004264google scholar: lookup
  25. Jacobs CC, Schnabel LV, McIlwraith CW, Blikslager AT. Non-steroidal anti-inflammatory drugs in equine orthopaedics. Equine Vet J 2022;54(4):636–648.
    doi: 10.1111/evj.13561pmc: PMC9304133pubmed: 35076950google scholar: lookup
  26. Jones SL, Davis J, Rowlingson K. Ultrasonographic findings in horses with right dorsal colitis: five cases (2000–2001). J Am Vet Med Assoc 2003;222(9):1248–1251.
    doi: 10.2460/javma.2003.222.1248pubmed: 12725314google scholar: lookup
  27. Karcher LF, Dill SG, Anderson WI, King JM. Right dorsal colitis. J Vet Intern Med 1990;4(5):247–253.
    doi: 10.1111/j.1939-1676.1990.tb03117.xpubmed: 2262926google scholar: lookup
  28. Lantz GC, Badylak SF, Hiles MC, Arkin TE. Treatment of reperfusion injury in dogs with experimentally induced gastric dilatation-volvulus. Am J Vet Res 1992;53(9):1594–1598.
    doi: 10.2460/ajvr.1992.53.09.1594pubmed: 1416361google scholar: lookup
  29. le Jeune S, Whitcomb MB. Ultrasound of the equine acute abdomen. Vet Clin North Am Equine Pract 2014;30(2):353–81, viii.
    pubmed: 25016496doi: 10.1016/j.cveq.2014.04.011google scholar: lookup
  30. Luthersson N, Nielsen KH, Harris P, Parkin TD. Risk factors associated with equine gastric ulceration syndrome (EGUS) in 201 horses in Denmark. Equine Vet J 2009;41(7):625–630.
    doi: 10.2746/042516409x441929pubmed: 19927579google scholar: lookup
  31. MacAllister CG. Effects of toxic doses of phenylbutazone in ponies. Am J Vet Res 1983;44(12):2277–2279.
    pubmed: 6660616
  32. MacAllister CG, Morgan SJ, Borne AT, Pollet RA. Comparison of adverse effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses. J Am Vet Med Assoc 1993;202(1):71–77.
    doi: 10.2460/javma.1993.202.01.71pubmed: 8420909google scholar: lookup
  33. MacKay RJ, French TW, Nguyen HT, Mayhew IG. Effects of large doses of phenylbutazone administration to horses. Am J Vet Res 1983;44(5):774–780.
    pubmed: 6869982
  34. McConnico RS, Morgan TW, Williams CC, Hubert JD, Moore RM. Pathophysiologic effects of phenylbutazone on the right dorsal colon in horses. Am J Vet Res 2008;69(11):1496–1505.
    doi: 10.2460/ajvr.69.11.1496pubmed: 18980433google scholar: lookup
  35. Meschter CL, Gilbert M, Krook L, Maylin G, Corradino R. The effects of phenylbutazone on the intestinal mucosa of the horse: a morphological, ultrastructural and biochemical study. Equine Vet J 1990;22(4):255–263.
    doi: 10.1111/j.2042-3306.1990.tb04264.xpubmed: 2209522google scholar: lookup
  36. Monreal L, Sabate D, Segura D, Mayos I, Homedes J. Lower gastric ulcerogenic effect of suxibuzone compared to phenylbutazone when administered orally to horses. Res Vet Sci 2004;76(2):145–149.
    doi: 10.1016/j.rvsc.2003.10.004pubmed: 14672858google scholar: lookup
  37. Murray MJ. Equine model of inducing ulceration in alimentary squamous epithelial mucosa. Dig Dis Sci 1994;39(12):2530–2535.
    doi: 10.1007/BF02087686pubmed: 7995175google scholar: lookup
  38. Murray MJ, Nout YS, Ward DL. Endoscopic findings of the gastric antrum and pylorus in horses: 162 cases (1996–2000). J Vet Intern Med 2001;15(4):401–406.
    doi: 10.1111/j.1939-1676.2001.tb02336.xpubmed: 11467600google scholar: lookup
  39. Naito Y, Yoshikawa T, Yoshida N, Kondo M. Role of oxygen radical and lipid peroxidation in indomethacin-induced gastric mucosal injury. Dig Dis Sci 1998;43(9 Suppl):30S–4S.
    pubmed: 9753223
  40. Nicol CJ, Davidson HP, Harris PA, Waters AJ, Wilson AD. Study of crib-biting and gastric inflammation and ulceration in young horses. Vet Rec 2002;151(22):658–662.
    doi: 10.1136/vr.151.22.658pubmed: 12498408google scholar: lookup
  41. Nieto JE, Aleman M, Anderson JD, Fiack C, Snyder JR. Effects of phenylbutazone on gene expression of cyclooxygenase-1 and– 2 in the oral, glandular gastric, and bladder mucosae of healthy horses. Am J Vet Res 2012;73(1):98–104.
    doi: 10.2460/ajvr.73.1.98pubmed: 22204294google scholar: lookup
  42. Nosalova V, Navarova J, Mihalova D, Sotnikova R. Mesenteric ischemia/reperfusion-induced intestinal and vascular damage: effect of stobadine. Methods Find Exp Clin Pharmacol 2007;29(1):39–45.
    doi: 10.1358/mf.2007.29.1.1063495pubmed: 17344943google scholar: lookup
  43. Pedersen SK, Cribb AE, Read EK, French D, Banse HE. Phenylbutazone induces equine glandular gastric disease without decreasing prostaglandin E(2) concentrations. J Vet Pharmacol Ther 2018;41(2):239–245.
    doi: 10.1111/jvp.12464pubmed: 29148168google scholar: lookup
  44. Reed SK, Messer NT, Tessman RK, Keegan KG. Effects of phenylbutazone alone or in combination with flunixin meglumine on blood protein concentrations in horses. Am J Vet Res 2006;67(3):398–402.
    doi: 10.2460/ajvr.67.3.398pubmed: 16506899google scholar: lookup
  45. Richards N, Hinch G, Rowe J. The effect of current grain feeding practices on hindgut starch fermentation and acidosis in the Australian racing Thoroughbred. Aust Vet J 2006;84(11):402–407.
    doi: 10.1111/j.1751-0813.2006.00059.xpubmed: 17092327google scholar: lookup
  46. Richardson LM, Whitfield-Cargile CM, Cohen ND, Chamoun-Emanuelli AM, Dockery HJ. Effect of selective versus nonselective cyclooxygenase inhibitors on gastric ulceration scores and intestinal inflammation in horses. Vet Surg 2018;47(6):784–791.
    doi: 10.1111/vsu.12941pubmed: 30094858google scholar: lookup
  47. Ricord M, Andrews FM, Yniguez FJM, Keowen M, Garza F Jr., Paul L, Chapman A, Banse HE. Impact of concurrent treatment with omeprazole on phenylbutazone-induced equine gastric ulcer syndrome (EGUS). Equine Vet J 2021;53(2):356–363.
    doi: 10.1111/evj.13323pubmed: 32697849google scholar: lookup
  48. Sanchez L. Disorders of the gastrointestinal system. 2018;In: Reed SM, Bayly WM, Sellon DC (eds) Equine internal medicine, 4th edn. Elsevier, St. Louis, pp 709–842.
  49. Sanchez S, Martin MJ, Ortiz P, Motilva V, de la Alarcon C. Effects of dipyrone on inflammatory infiltration and oxidative metabolism in gastric mucosa: comparison with acetaminophen and diclofenac. Dig Dis Sci 2002;47(6):1389–1398.
    doi: 10.1023/a:1015395103160pubmed: 12064817google scholar: lookup
  50. Shawaf T, El-Deeb WM, Elgioushy M. The contribution of specific and nonspecific biomarkers in diagnosis of equine gastric ulcer syndrome (EGUS) under field condition. J Equine Vet Sci 2020;84:102853.
    doi: 10.1016/j.jevs.2019.102853pubmed: 31864460google scholar: lookup
  51. Singh Z, Karthigesu IP, Singh P, Rupinder K. Use of malondialdehyde as a biomarker for assessing oxidative stress in different disease pathologies: a review. Iran J Public Health 2014;43(Supple 3):7–16.
  52. Soma LR, Uboh CE, Maylin GM. The use of phenylbutazone in the horse. J Vet Pharmacol Ther 2012;35(1):1–12.
    doi: 10.1111/j.1365-2885.2011.01299.xpubmed: 21668837google scholar: lookup
  53. Sykes BW, Hewetson M, Hepburn RJ, Luthersson N, Tamzali Y. European College of Equine Internal Medicine Consensus Statement–equine gastric ulcer syndrome in adult horses. J Vet Intern Med 2015;29(5):1288–1299.
    doi: 10.1111/jvim.13578pmc: PMC4858038pubmed: 26340142google scholar: lookup
  54. Tesena P, Yingchutrakul Y, Roytrakul S, Wongtawan T, Angkanaporn K. Serum protein expression in equine glandular gastric disease (EGGD) induced by phenylbutazone. J Vet Med Sci 2019;81(3):418–424.
    doi: 10.1292/jvms.18-0679pmc: PMC6451916pubmed: 30674748google scholar: lookup
  55. Tobin T, Chay S, Kamerling S, Woods WE, Weckman TJ, Blake JW, Lees P. Phenylbutazone in the horse: a review. J Vet Pharmacol Ther 1986;9(1):1–25.
    doi: 10.1111/j.1365-2885.1986.tb00008.xpubmed: 3517382google scholar: lookup
  56. van Galen G, Saegerman C, Hyldahl Laursen S, Jacobsen S, Andersson Munk M, Sjostrom H, Holm Lindmark S, Verwilghen D. Colonic health in hospitalized horses treated with non-steroidal anti-inflammatory drugs - a preliminary study. J Equine Vet Sci 2021;101:103451.
    doi: 10.1016/j.jevs.2021.103451pubmed: 33993934google scholar: lookup
  57. Vinijkumthorn R, Bauck AG, Vidyasagar S, Freeman DE. Nonsteroidal antiinflammatory drugs reduce anion secretion and increase apoptosis in equine colonic mucosa ex vivo. Am J Vet Res 2024;85(1).
    pubmed: 38113643doi: 10.2460/ajvr.23.08.0182google scholar: lookup
  58. Zuluaga Cabrera A, Alves GE, Martinez J. Nitric oxide and malondialdehyde in gastric contents and blood in an equine model of gastric ulcer induced by phenylbutazone. Rev Colomb Cienc Pecu 2016;29:43–50.
    doi: 10.17533/udea.rccp.v29n1a05google scholar: lookup
  59. Zushi S, Shinomura Y, Kiyohara T, Minami T, Sugimachi M, Higashimoto Y, Kanayama S, Matsuzawa Y. Role of prostaglandins in intestinal epithelial restitution stimulated by growth factors. Am J Physiol 1996;270(5 Pt 1):G757–G762.
    doi: 10.1152/ajpgi.1996.270.5.G757pubmed: 8967486google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.